OverviewSuggest Edit

Unity Biotechnology designs therapeutics that prevent various diseases of aging. The company focuses on clearing senescent cells and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
TypePublic
Founded2009
HQSan Francisco, US
Websiteunitybiotechnology.com

Latest Updates

Employees (est.) (May 2017)7
Share Price (Oct 2019)$7

Key People/Management at UNITY Biotechnology

Keith R. Leonard

Keith R. Leonard

CEO
Bob Goeltz

Bob Goeltz

CFO
Nathaniel David

Nathaniel David

President
Jamie Dananberg

Jamie Dananberg

Chief Medical Officer
D. Dan Marquess

D. Dan Marquess

Chief Scientific Officer
Tamara Tompkins

Tamara Tompkins

General Counsel
Show more

UNITY Biotechnology Office Locations

UNITY Biotechnology has an office in San Francisco
San Francisco, US (HQ)
San Francisco
Show all (1)

UNITY Biotechnology Financials and Metrics

UNITY Biotechnology Revenue

Market capitalization (18-Oct-2019)

303.3m

Closing stock price (18-Oct-2019)

7.0
UNITY Biotechnology's current market capitalization is $303.3 m.
Show all financial metrics

UNITY Biotechnology Online and Social Media Presence

Embed Graph

UNITY Biotechnology News and Updates

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Program Updates

SAN FRANCISCO, March 06, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported business highlights and financial results for the fourth quarter…

UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye

SAN FRANCISCO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging, today announced it has selected UBX1967 as the lead development candidat…

UNITY Biotechnology, Inc. to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Keith Leonard, chairman and chief executive officer, wil…

UNITY Biotechnology Blogs

UNITY Biotechnology, Inc. to Participate in the 2019 Cantor Global Healthcare Conference

SAN FRANCISCO , Sept. 20, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate

UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences

SAN FRANCISCO , Aug. 27, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate at

UNITY Biotechnology, Inc. Reports Second Quarter 2019 Financial Results and Program Updates

SAN FRANCISCO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter ended June 30, 2019 .

UNITY Biotechnology, Inc. Announces Plan for Phase 2 Clinical Study of UBX0101 in Osteoarthritis of the Knee

SAN FRANCISCO , July 30, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced details for the planned Phase 2 study of UBX0101 in patients

UNITY Biotechnology, Inc. To Announce Second Quarter 2019 Financial Results

SAN FRANCISCO , July 30, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the second quarter ended June 30, 2019 , on

UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee

Clinical results support senescent cell elimination with UBX0101 as a potential treatment for osteoarthritis Topline results demonstrate a dose-dependent and clinically meaningful impact on pain Call with management scheduled for today at 8:00 a.m. EDT SAN FRANCISCO , June 18, 2019 (GLOBE NEWSWIRE)
Show more

UNITY Biotechnology Frequently Asked Questions

  • When was UNITY Biotechnology founded?

    UNITY Biotechnology was founded in 2009.

  • Who are UNITY Biotechnology key executives?

    UNITY Biotechnology's key executives are Keith R. Leonard, Bob Goeltz and Nathaniel David.

  • How many employees does UNITY Biotechnology have?

    UNITY Biotechnology has 7 employees.

  • Who are UNITY Biotechnology competitors?

    Competitors of UNITY Biotechnology include Urovant Sciences, Verrica Pharmaceuticals and Deciphera Pharmaceuticals.

  • Where is UNITY Biotechnology headquarters?

    UNITY Biotechnology headquarters is located at San Francisco, San Francisco.

  • Where are UNITY Biotechnology offices?

    UNITY Biotechnology has an office in San Francisco.

  • How many offices does UNITY Biotechnology have?

    UNITY Biotechnology has 1 office.